Effect of chronic subcutaneous minipump infusion of lisuride upon locomotor activity of rats

  • H. Wachtel
  • K.-J. Rettig
  • P.-A. Löschmann
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)


Male Wistar rats were infused continuously for 14 days with lisuride 0.25mg/kg/day or with vehicle via subcutaneously implanted osmotic mini-pumps. Locomotor activity was measured at 5 hours, 1, 7 and 14 days after implantation. Thereafter the minipumps were removed and 1, 7 and 21 days later the locomotor activity was recorded after a subcutaneous challenge dose of lisuride 0.1 mg/kg. In the course of continuous infusion the lisuride-treated rats showed a persistent stimulation of locomotor activity which remained almost constant throughout the whole period of exposure. At all intervals after removal of the minipumps lisuride challenge produced a less pronounced locomotor stimulation in lisuride-infused rats compared to vehicle-infused animals. This observation contrasts with the findings after chronic subcutaneous bolus treatment of rats with 0.25 mg/kg lisuride once daily for 29 days which resulted (1) in a progressive enhancement of the locomotor stimulatory effect and (2) in a longlasting hyperresponsiveness towards a subcutaneous challenge dose of lisuride 0.025 mg/kg. These results are discussed with respect to the advantage of the constant availability of lisuride at central dopamine receptors for the management of patients with advanced Parkinson’s disease showing fluctuations in motor performance probably related to the kinetics of conventional oral therapy.


Osmotic Minipumps Locomotor Stimulation Mini Pump Locomotor Stimulatory Effect Continuous Dopaminergic Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Castro R, Abreu P, Calzadilla CH, Rodriguez M (1985) Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacology 85: 333–339PubMedCrossRefGoogle Scholar
  2. Dorow R, Gräf KJ, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopaminergic agonists and neuroendocrine function. Acta Endocrinol [Suppl 234] (Copenh) 94: 9Google Scholar
  3. Gopinathan G, Teraväinen H, Dambrosia JN, Ward CD, Sanes JH, Stuart WK, Evarts EV, Calne DB (1981) Lisuride in parkinsonism. Neurology 31: 371–376PubMedCrossRefGoogle Scholar
  4. Lieberman A, Leibowitz M, Neophytides A, Kupersmith M, Mehl S, Kleinberg D, Serby M, Goldstein M (1979) Pergolide and lisuride for Parkinson’s disease. Lancet 2: 1129–1130PubMedCrossRefGoogle Scholar
  5. Nielsen EB (1981) Rapid decline of stereotyped behavior in rats during constant one week administration of amphetamine via implanted Alzet osmotic minipumps. Pharmacol Biochem Behav 15: 161–165PubMedCrossRefGoogle Scholar
  6. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
  7. Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson’s disease: response to intravenous infusion of levodopa. Lancet 2: 412–415PubMedCrossRefGoogle Scholar
  8. Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431–442Google Scholar
  9. Schachter M, Blackstock J, Dick JPR, George RJD, Marsden CD, Parkes JD (1979) Lisuride in Parkinson’s disease. Lancet 2: 1129PubMedCrossRefGoogle Scholar
  10. Stibe C, Lees A, Stern G (1987) Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1: 871PubMedCrossRefGoogle Scholar
  11. Stocchi F, Ruggieri S, Brughitta G, Agnoli A (1986) Problems in daily motor performances in Parkinson’s disease: the continuous dopaminergic stimulation. J Neural Transm [Suppl] 22: 209–218Google Scholar
  12. Wachtel H, Zehleke P, Schlangen M (1980) Supersensitivity following the chronic administration of the dopaminergic ergot derivative lisuride hydrogen maleate (LHM) to rats. Naunyn Schmiedebergs Arch Pharmacol [Suppl] 311: R70Google Scholar
  13. Wachtel H (1983) Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 109–125Google Scholar
  14. Wright LS, Horn HJ, Woodard G (1962) Activity patterns in mice tested singly and in groups as a drug screening tool. Fed Proc 21: 420Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • H. Wachtel
    • 1
  • K.-J. Rettig
    • 1
  • P.-A. Löschmann
    • 1
  1. 1.Research Laboratories of Schering AGBerlin and BergkamenFederal Republic of Germany

Personalised recommendations